These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 11552226)

  • 81. Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?
    Perez EA
    Curr Oncol Rep; 2003 Jan; 5(1):66-71. PubMed ID: 12493153
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
    von Minckwitz G; Raab G; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Tulusan AH; Gademann G; Sinn HP; Caputo A; Graf E; Kaufmann M
    Zentralbl Gynakol; 2001 Sep; 123(9):497-504. PubMed ID: 11709742
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Non-pegylated doxorubicin (Myocet®) as the less cardiotoxic alternative of free doxorubicin].
    Nagykálnai T
    Magy Onkol; 2010 Dec; 54(4):359-67. PubMed ID: 21163767
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Effectiveness of doxorubicin-docetaxel or doxorubicin-cyclophosphamide combination in advanced breast cancer with distant metastasis].
    Szántó J; Pintér T; Szántó J
    Orv Hetil; 2001 Apr; 142(14):723-6. PubMed ID: 11341166
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.
    Conte P; Gennari A; Guarneri V; Landucci E; Donati S; Salvadori B; Bengala C; Orlandini C; Baldini E
    Oncology (Williston Park); 2001 May; 15(5 Suppl 7):21-3. PubMed ID: 11396360
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Neoadjuvant chemotherapy of breast cancer.
    Garces CA; Cance WG
    Am Surg; 2004 Jul; 70(7):565-9. PubMed ID: 15279176
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer.
    Perez EA
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S52-6. PubMed ID: 11970750
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
    Crown J; Pegram M
    Breast Cancer Res Treat; 2003; 79 Suppl 1():S11-8. PubMed ID: 12868801
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Combination of taxotere and doxorubicin in chemotherapy of disseminated breast cancer].
    Poddubnaia IV; Manziuk LV; Artamonova EV; Arkad'eva TV; Davidenko IS
    Vopr Onkol; 2001; 47(6):728-30. PubMed ID: 11826498
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Paclitaxel: epirubicin in metastatic breast cancer--a review.
    Razis ED; Fountzilas G
    Ann Oncol; 2001 May; 12(5):593-8. PubMed ID: 11432615
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation.
    Zambetti M; Moliterni A; Materazzo C; Stefanelli M; Cipriani S; Valagussa P; Bonadonna G; Gianni L
    J Clin Oncol; 2001 Jan; 19(1):37-43. PubMed ID: 11134193
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report.
    Friedrichs K; Hölzel F; Jänicke F
    Eur J Cancer; 2002 Sep; 38(13):1730-8. PubMed ID: 12175689
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Liposomal anthracyclines in metastatic breast cancer: clinical update.
    Rivera E
    Oncologist; 2003; 8 Suppl 2():3-9. PubMed ID: 13679590
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Metastatic breast cancer.
    Kennedy MJ
    Curr Opin Oncol; 1996 Nov; 8(6):485-90. PubMed ID: 8971468
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Advances in the use of taxanes in the adjuvant therapy of breast cancer.
    Nabholtz JM; Vannetzel JM; Llory JF; Bouffette P
    Clin Breast Cancer; 2003 Aug; 4(3):187-92. PubMed ID: 14499011
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Taxanes in the first-line chemotherapy of metastatic breast cancer: review.
    Friedrich M; Diesing D; Villena-Heinsen C; Felberbaum R; Kolberg HC; Diedrich K
    Eur J Gynaecol Oncol; 2004; 25(1):66-70. PubMed ID: 15053065
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pre-operative cardiac workup after anthracycline-based neoadjuvant chemotherapy. Is it really necessary?
    Shapiro R; Barsuk D; Segev L; Shimon-Paluch S; Berkenstadt H; Zippel DB; Papa MZ
    Ann R Coll Surg Engl; 2011 Mar; 93(2):127-9. PubMed ID: 21092416
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
    Kaklamani VG; Gradishar WJ
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S26-33. PubMed ID: 12756076
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
    Platel D; Pouna P; Bonoron-Adèle S; Robert J
    Toxicol Appl Pharmacol; 2000 Mar; 163(2):135-40. PubMed ID: 10698671
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Current status and perspectives of chemotherapy for anthracycline-pretreated breast cancer].
    Heinemann V
    Onkologie; 2003 Dec; 26 Suppl 7():11-6. PubMed ID: 14716136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.